Your browser doesn't support javascript.
loading
Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
Fabbro-Peray, Pascale; Zouaoui, Sonia; Darlix, Amélie; Fabbro, Michel; Pallud, Johan; Rigau, Valérie; Mathieu-Daude, Hélène; Bessaoud, Faiza; Bauchet, Fabienne; Riondel, Adeline; Sorbets, Elodie; Charissoux, Marie; Amelot, Aymeric; Mandonnet, Emmanuel; Figarella-Branger, Dominique; Duffau, Hugues; Tretarre, Brigitte; Taillandier, Luc; Bauchet, Luc.
Afiliación
  • Fabbro-Peray P; Department of Biostatistics, Epidemiology, Public Health, CHU Nîmes, Nîmes, France.
  • Zouaoui S; EA2415 Research Unit, Montpellier University, Montpellier, France.
  • Darlix A; Department of Neurosurgery, Hopital Gui de Chauliac, CHU Montpellier, Montpellier University Medical Center, 80 Avenue Fliche, 34295, Montpellier, France.
  • Fabbro M; INSERM U1051, Montpellier, France.
  • Pallud J; Groupe de Neuro-Oncologie du Languedoc Roussillon, ICM, Montpellier, France.
  • Rigau V; Groupe de Neuro-Oncologie du Languedoc Roussillon, ICM, Montpellier, France.
  • Mathieu-Daude H; Department of Medical Oncology, ICM, Montpellier, France.
  • Bessaoud F; Groupe de Neuro-Oncologie du Languedoc Roussillon, ICM, Montpellier, France.
  • Bauchet F; Department of Medical Oncology, ICM, Montpellier, France.
  • Riondel A; Department of Neurosurgery, Sainte Anne Hospital, and University Paris Descartes, Paris, France.
  • Sorbets E; Groupe de Neuro-Oncologie du Languedoc Roussillon, ICM, Montpellier, France.
  • Charissoux M; Department of Neuropathology, Hopital Gui de Chauliac, CHU Montpellier, Montpellier University Medical Center, Montpellier, France.
  • Amelot A; Groupe de Neuro-Oncologie du Languedoc Roussillon, ICM, Montpellier, France.
  • Mandonnet E; Department of Medical informatics, ICM, Montpellier, France.
  • Figarella-Branger D; Registre des Tumeurs de l'Hérault, ICM, Montpellier, France.
  • Duffau H; Groupe de Neuro-Oncologie du Languedoc Roussillon, ICM, Montpellier, France.
  • Tretarre B; Department of Biostatistics, Epidemiology, Public Health, CHU Nîmes, Nîmes, France.
  • Taillandier L; EA2415 Research Unit, Montpellier University, Montpellier, France.
  • Bauchet L; Department of Biostatistics, Epidemiology, Public Health, CHU Nîmes, Nîmes, France.
J Neurooncol ; 142(1): 91-101, 2019 Mar.
Article en En | MEDLINE | ID: mdl-30523606
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pautas de la Práctica en Medicina / Neoplasias Encefálicas / Glioblastoma / Antineoplásicos Alquilantes / Temozolomida Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurooncol Año: 2019 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pautas de la Práctica en Medicina / Neoplasias Encefálicas / Glioblastoma / Antineoplásicos Alquilantes / Temozolomida Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurooncol Año: 2019 Tipo del documento: Article País de afiliación: Francia